Exact FDA event identifier

Event 65172

11 recalled-product records grouped only because every row carries this exact official event ID.

Event summary

Timeline bucket: April 30, 2013
Product types: Drug
Classifications: Class II
Statuses: Terminated
Recalling firm wording: King Legacy, a wholly owned subsidiary of Pfizer

Dossier provenance

Source snapshots represented here

openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Device root-cause evidence is not applicable to this event. No grouped product has the official product type device; this is not an unavailable-enrichment finding.

Complete imported group

Every recalled product in this event

11 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 11

Levoxyl (levothyroxine sodium) tablets, USP, 25 mcg, packaged in a) 100-count bottles (NDC 60793-850-01) and b) 1000-count bottles (NDC 60793-850-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620

D-421-2013

Recall number: D-421-2013
Initiated: April 30, 2013
Classification: Class II
Status: Terminated
Recalling firm: King Legacy, a wholly owned subsidiary of Pfizer
Quantity: 51,591 bottles

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent Drug: The products were below specification for potency at the expiry stability point.

Code information

Lot # a) 65228, Exp. 06/13; 65636, Exp. 08/13; b) 65180, Exp. 05/13; 65769, Exp. 07/13

Distribution pattern

Nationwide and Puerto Rico

drug · product 2 of 11

Levoxyl (levothyroxine sodium) tablets, USP, 50 mcg, packaged in a) 100-count bottles (NDC 60793-851-01) and b) 1000-count bottles (NDC 60793-851-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620

D-422-2013

Recall number: D-422-2013
Initiated: April 30, 2013
Classification: Class II
Status: Terminated
Recalling firm: King Legacy, a wholly owned subsidiary of Pfizer
Quantity: 195,699 bottles

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent Drug: The products were below specification for potency at the expiry stability point.

Code information

Lot # a) 64934, Exp. 4/13; 65059, Exp. 5/13; 65179, Exp. 4/13; 65630, Exp. 7/13; 65916, Exp. 8/13; 66367, Exp. 10/13; and 66718, Exp. 11/13; b) 64338, Exp. 4/13; 64932, Exp. 4/13; 65060, Exp. 5/13; 65235, Exp. 6/13; 65853, Exp. 6/13; and 65962, Exp. 7/13

Distribution pattern

Nationwide and Puerto Rico

drug · product 3 of 11

Levoxyl (levothyroxine sodium) tablets, USP, 75 mcg, packaged in a) 100-count bottles (NDC 60793-852-01) and b) 1000-count bottles (NDC 60793-852-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620

D-423-2013

Recall number: D-423-2013
Initiated: April 30, 2013
Classification: Class II
Status: Terminated
Recalling firm: King Legacy, a wholly owned subsidiary of Pfizer
Quantity: 194,142 bottles

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent Drug: The products were below specification for potency at the expiry stability point.

Code information

Lot # a) 64197, Exp. 4/13; 64339, Exp. 4/13; 65061, Exp. 5/13; 65236, Exp. 6/13; 65917, Exp. 8/13; 66122, Exp. 8/13; and 66427, Exp. 9/13; b) 64340, Exp. 4/13; 64933, Exp. 4/13; 65062, Exp. 5/13; 65237, Exp. 6/13; 65238, Exp. 6/13; and 66121, Exp. 8/13

Distribution pattern

Nationwide and Puerto Rico

drug · product 4 of 11

Levoxyl (levothyroxine sodium) tablets, USP, 88 mcg, packaged in a) 100-count bottles (NDC 60793-853-01) and b) 1000-count bottles (NDC 60793-853-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620

D-424-2013

Recall number: D-424-2013
Initiated: April 30, 2013
Classification: Class II
Status: Terminated
Recalling firm: King Legacy, a wholly owned subsidiary of Pfizer
Quantity: 112,914 bottles

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent Drug: The products were below specification for potency at the expiry stability point.

Code information

Lot # a) 64935, Exp. 5/13; 65239, Exp. 6/13; 65900, Exp. 8/13; 66370, Exp. 10/13; and 66391, Exp. 9/13; b) 64927, Exp. 5/13; and 65240, Exp. 6/13

Distribution pattern

Nationwide and Puerto Rico

drug · product 5 of 11

Levoxyl (levothyroxine sodium) tablets, USP, 100 mcg, packaged in a) 100-count bottles (NDC 60793-854-01) and b) 1000-count bottles (NDC 60793-854-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620

D-425-2013

Recall number: D-425-2013
Initiated: April 30, 2013
Classification: Class II
Status: Terminated
Recalling firm: King Legacy, a wholly owned subsidiary of Pfizer
Quantity: 195,201 bottles

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent Drug: The products were below specification for potency at the expiry stability point.

Code information

Lot # a) 64341, Exp 04/13; 64928, Exp. 5/13; 65064, Exp. 5/13; 65233, Exp. 7/13; 66162, Exp. 8/13; 66365, Exp. 10/13; and 66677, Exp. 11/13; b) 64342, Exp. 4/13; 64929, Exp. 5/13; 65065, Exp. 5/13; 65234, Exp. 7/13; 65539, Exp. 7/13; 65901, Exp. 8/13; and 66163, Exp. 8/13

Distribution pattern

Nationwide and Puerto Rico

drug · product 6 of 11

Levoxyl (levothyroxine sodium) tablets, USP, 112 mcg, packaged in a) 100-count bottles (NDC 60793-855-01) and b) 1000-count bottles (NDC 60793-855-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620

D-426-2013

Recall number: D-426-2013
Initiated: April 30, 2013
Classification: Class II
Status: Terminated
Recalling firm: King Legacy, a wholly owned subsidiary of Pfizer
Quantity: 107,236 bottles

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent Drug: The products were below specification for potency at the expiry stability point.

Code information

Lot # a) 64936, Exp. 5/13; 65634, Exp. 7/13; 66295, Exp. 9/13; 66669, Exp. 11/13; b) 65063, Exp. 5/13 and 65767, Exp. 7/13

Distribution pattern

Nationwide and Puerto Rico

drug · product 7 of 11

Levoxyl (levothyroxine sodium) tablets, USP, 125 mcg, packaged in a) 100-count bottles (NDC 60793-856-01) and b) 1000-count bottles (NDC 60793-856-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620

D-427-2013

Recall number: D-427-2013
Initiated: April 30, 2013
Classification: Class II
Status: Terminated
Recalling firm: King Legacy, a wholly owned subsidiary of Pfizer
Quantity: 103,796 bottles

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent Drug: The products were below specification for potency at the expiry stability point.

Code information

Lot # a) 64333, Exp. 5/13; 64937, Exp. 6/13; 65629, Exp. 7/13; and 66296, Exp. 9/13; b) 64931, Exp. 5/13 and 65766, Exp. 7/13

Distribution pattern

Nationwide and Puerto Rico

drug · product 8 of 11

Levoxyl (levothyroxine sodium) tablets, USP, 137 mcg, packaged in a) 100-count bottles (NDC 60793-857-01) and b) 1000-count bottles (NDC 60793-857-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620

D-428-2013

Recall number: D-428-2013
Initiated: April 30, 2013
Classification: Class II
Status: Terminated
Recalling firm: King Legacy, a wholly owned subsidiary of Pfizer
Quantity: 77,272 bottles

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent Drug: The products were below specification for potency at the expiry stability point.

Code information

Lot # a) 64190, Exp. 4/13; 64331, Exp. 6/13; 65642, Exp. 7/13; and 66297, Exp. 9/13; b) 64326, Exp. 4/13; 64332, Exp. 6/13; and 65771, Exp. 7/13

Distribution pattern

Nationwide and Puerto Rico

drug · product 9 of 11

Levoxyl (levothyroxine sodium) tablets, USP, 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles (NDC 60793-858-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620

D-429-2013

Recall number: D-429-2013
Initiated: April 30, 2013
Classification: Class II
Status: Terminated
Recalling firm: King Legacy, a wholly owned subsidiary of Pfizer
Quantity: 56,405 bottles

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent Drug: The products were below specification for potency at the expiry stability point.

Code information

Lot # a) 65066, Exp. 5/13 and 65644, Exp. 7/13; b) 64327, Exp. 4/13 and 65772, Exp. 7/13

Distribution pattern

Nationwide and Puerto Rico

drug · product 10 of 11

Levoxyl (levothyroxine sodium) tablets, USP, 175 mcg, packaged in a) 100-count bottles (NDC 60793-859-01) and b) 1000-count bottles (NDC 60793-859-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620

D-430-2013

Recall number: D-430-2013
Initiated: April 30, 2013
Classification: Class II
Status: Terminated
Recalling firm: King Legacy, a wholly owned subsidiary of Pfizer
Quantity: 51,438 bottles

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent Drug: The products were below specification for potency at the expiry stability point.

Code information

Lot # a) 64329, Exp. 5/13; 65229, Exp. 6/13; and 65913, Exp. 9/13; b) 64330, Exp. 5/13; 65230, Exp. 6/13; and 65915, Exp. 9/13

Distribution pattern

Nationwide and Puerto Rico

drug · product 11 of 11

Levoxyl (levothyroxine sodium) tablets, USP, 200 mcg, packaged in a) 100-count bottles (NDC 60793-860-01) and b) 1000-count bottles (NDC 60793-860-10), Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620

D-431-2013

Recall number: D-431-2013
Initiated: April 30, 2013
Classification: Class II
Status: Terminated
Recalling firm: King Legacy, a wholly owned subsidiary of Pfizer
Quantity: 33,227 bottles

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent Drug: The products were below specification for potency at the expiry stability point.

Code information

Lot # a) 64301, Exp. 4/13 and 65628, Exp. 7/13; b) 64300, Exp. 4/13 and 65765, Exp. 7/13

Distribution pattern

Nationwide and Puerto Rico